GlassScriptPhysician profile
Joel Roy Brunt
NPI 1689672156
$3,648.15
in general payments reported to CMS, 2019-2025
22 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $373 · 2021: $664 · 2022: $263 · 2023: $218 · 2024: $999 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $867.85 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $502.20 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $349.76 | 2021-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $330.63 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $280.87 | 2019-2025 | Jynarque |
| Amgen INC. | $278.91 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $182.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $146.47 | 2024-2025 | |
| Travere Therapeutics, INC. | $116.78 | 2024-2025 | |
| Daiichi Sankyo INC. | $92.66 | 2021-2022 | |
| Akebia Therapeutics INC | $90.06 | 2021-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $88.91 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $53.39 | 2023-2024 | Jardiance |
| Renalytix Ai, INC. | $46.47 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Hospital Products INC. | $41.27 | 2021-2025 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.02 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.77 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $27.70 | 2024 | Lupkynis |
| Ardelyx, INC. | $27.07 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2020 | |
| Mallinckrodt Enterprises LLC | $16.30 | 2019 | |
| Horizon Therapeutics Plc | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Brunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.